Guanfacine (Intuniv)

Guanfacine is one of those drugs that quietly does a lot of work and almost nobody talks about. It started life as a blood pressure pill in the 1980s and ended up, by accident, being one of the more useful tools in ADHD treatment. The brand most people see now is Intuniv, which is the extended-release version. Tenex is the older immediate-release tablet, still around, still cheap.

It isn’t a stimulant. That’s the first thing patients want to know, usually because they’ve already tried a stimulant and either couldn’t tolerate it or didn’t want to go near one in the first place. Guanfacine works on a totally different system. It’s a selective alpha-2A adrenergic agonist, which sounds like a mouthful but really just describes which receptors it hits and where.

And in the kids who come in irritable, dysregulated, blowing up at their parents over nothing, exploding at homework, the picture isn’t always classic inattentive ADHD. It’s something more like a frayed thermostat. That’s the patient where guanfacine tends to earn its keep.

The prefrontal cortex angle, in plain language

The prefrontal cortex is the part of your brain right behind your forehead. It does the boring grown-up jobs: planning, holding stuff in working memory, inhibiting impulses, putting the brakes on emotional reactions before they become outbursts. In ADHD, the working theory for the last twenty years is that this region is underpowered, particularly its noradrenergic signaling.

Stimulants help by raising dopamine and norepinephrine across that region in a fairly blunt way. Guanfacine does something stranger and more local. It binds to alpha-2A receptors that sit on the prefrontal cortex neurons themselves, and binding there strengthens the signal-to-noise ratio of those circuits. Amy Arnsten’s lab at Yale spent decades working this out in monkeys. The effect, in human terms, is that the kid’s prefrontal cortex can actually do its job of overriding the limbic system instead of getting drowned out by it.

That’s why the kids who improve most on guanfacine aren’t necessarily the ones who can’t focus. They’re the ones who go from zero to screaming in four seconds. The drug doesn’t sedate the emotion. It gives the top-down brakes enough bandwidth to engage.

The kid use case: hyperactivity, reactivity, and the dysregulated 8-year-old

The classic guanfacine kid in my practice is somewhere between 6 and 12, often a boy though not always, and the chief complaint from the parents isn’t “he can’t pay attention in class.” It’s “we can’t get through breakfast without a meltdown.” Homework is a war. Transitions are a war. Bedtime is a war. The teacher is sending notes home about hitting or about getting up from his desk fifteen times in an hour.

One I think about often was an 8-year-old whose mother walked in carrying a binder. Two failed stimulant trials in the binder. Methylphenidate had him rage-storming about an hour after each dose. The amphetamine they tried next looked the same, only louder. By the time he hit my office she was running on three hours of sleep a night and had stopped inviting his cousins over because the last birthday party ended with a chair through a wall. We started Intuniv at 1 mg at night and titrated up to 3 mg over about six weeks. By week four she called me and said the mornings had stopped being a battlefield. He could sit at the breakfast table without breaking it. The kid she remembered from age five was back, just a little quieter at 7 AM.

That’s the use case nobody puts in the marketing material. Guanfacine is genuinely good at irritability and emotional reactivity in kids whose ADHD comes packaged with a fragile temper. The 2009 pediatric trials for Intuniv showed improvements on ADHD rating scales, but a lot of clinicians who use it routinely will tell you the family-level change is in the affect, not the attention.

You can dose attention with a stimulant. Dosing the temper is harder, and guanfacine is one of the few tools that does it without flattening the kid.

Adults, adjuncts, and the stimulant-intolerant patient

In adults the story is different and the evidence base is thinner, but it’s getting used more. Two scenarios.

First: the adult who responds beautifully to a stimulant but at a dose that gives them rebound irritability in the late afternoon, or sleep-onset problems even when dosed early. Adding 1 to 2 mg of guanfacine ER in the evening takes the edge off both. The stimulant still does the daytime work. The guanfacine catches the tail.

Second: the adult who can’t take a stimulant at all. Could be a cardiac history, a substance use history, a job that disqualifies them from controlled substances, or a body that just doesn’t tolerate the wired feeling. Guanfacine monotherapy in adults won’t give you the dramatic on-switch a stimulant does. It’s a quieter effect, usually a 20 to 40 percent improvement, often enough to matter for executive function and emotional regulation. Doses run higher in adults, sometimes up to 6 or 7 mg ER.

Clonidine is the cousin drug in this same alpha-2 family, less selective, more sedating, sometimes used the same way. Guanfacine is the cleaner choice for most cognitive work because it hits the 2A subtype more specifically.

Cardiovascular monitoring and the sedation problem

This is an antihypertensive. That’s not a side effect, that’s the original indication. Which means before you start it you check blood pressure and heart rate, and you check them again as you titrate. In kids the drops are usually modest. A 5 to 10 mmHg drop in systolic, a heart rate down by 5 to 8 beats per minute. Most kids don’t feel it. Some do.

The patients who get into trouble are the ones with an already-low baseline blood pressure, the ones who are dehydrated from a stomach bug while still taking it, or the ones who come off it too fast and rebound. Don’t stop guanfacine abruptly at higher doses. You taper. Same logic as any centrally acting antihypertensive.

Sedation is the other big one and it’s the reason almost everybody doses Intuniv at bedtime. The first two weeks can be genuinely sleepy in the morning. That usually fades. If it doesn’t, you split the dose or move it earlier. Parents of kids who’ve been bedtime-resistant for years often notice the sleep-onset benefit within the first week. The kid winds down faster, stops fighting bedtime, falls asleep without the usual three-hour negotiation. That’s worth saying out loud.

Why it’s underused

Two reasons. First, primary care prescribers and a fair number of psychiatrists still think of guanfacine as a blood pressure pill, which means it doesn’t come to mind when an irritable kid walks in the door. Stimulants are the reflex. Strattera maybe. Guanfacine sits a layer down in most prescribers’ mental hierarchy and a lot of kids who’d benefit never get tried on it.

Second, the onset is slower than a stimulant. Stimulants work the day you take them, which makes them satisfying to prescribe. Guanfacine takes two to four weeks to show its real effect, and parents who’ve heard about stimulant-day-one transformation get impatient. If you don’t set the expectation up front, the family bails at week two and you lose a drug that might have worked.

The kids it helps most aren’t going to start pulling straight A’s once they can focus. They’re the ones whose teachers stop calling home. They’re the ones whose siblings stop being afraid of them. The whole-family math shifts. Mom sleeps. The sibling stops flinching at the door slam. The kid himself starts to like himself again, which is the thing nobody charts and the thing that matters most.